14th Nov 2008 07:00
Sinclair Pharma plc
Additional listing
Godalming, UK, 14 November 2008: Sinclair Pharma plc (SPH.L) (the "Company"), the international specialty pharmaceutical company, today announces that application has been made for 1,956,521 ordinary shares of 1 pence each (the "New Ordinary Shares") in the Company to be admitted to the Official List of the UK Listing Authority and to trading on the London Stock Exchange. The New Ordinary Shares rank pari passu in all respects with the existing issued ordinary shares on the Company and it is expected that dealings will commence on 18 November 2008.
The New Ordinary Shares are being issued in relation to the share subscriptions by Michael Flynn, Chief Executive Officer, and Jean-Charles Tschudin, Non-Executive Director, announced on 31 October 2008.
Following admission, Mr Flynn and his connected parties and Mr Tschudin will have the following interest in the ordinary shares of the Company:
|
Director |
Shares subscribed for |
Holding following subscription |
% of issued voting share capital |
|
Michael Flynn |
1,739,130 |
11,801,130 |
12.3 |
|
Jean-Charles Tschudin |
217,391 |
442,391 |
0.5 |
Enquiries
For further information please contact:
Sinclair Pharma plc - Tel: +44 (0)1483 410 600
Dr Michael Flynn, CEO
Jerry Randall, CFO
About Sinclair Pharma Plc www.sinclairpharma.com
Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 80 countries.
Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short timeframe. The company focuses on niche therapeutic areas and its current portfolio includes products for a wide range of dermatological conditions and oral health.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.
Related Shares:
Sinclair Pharma